Tourmaline Bio Operating Income

Tourmaline Bio (TRML) currently reports a operating income of $-100M as of June 2025. That compares with $-44M in the prior-year period — down 131.2% year over year. Use the charts on this page to explore Tourmaline Bio's operating income history and peer comparisons.

Tourmaline Bio's operating income decreased from $-44M to $-100M — a 131.2% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tourmaline Bio reported $-100M in operating income as of June 2025. That compares with $-44M in the prior-year period — down 131.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tourmaline Bio, and consider following TRML for alerts when major investors trade the stock.

Tourmaline Bio is classified in the Healthcare sector. On operating income, it currently shows $-100M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRML with unrelated industries.